Medigard Ltd. has entered into an exclusive license agreement with Shanghai Sol-Millennium Medical Products Co. Ltd. The agreement grants Sol Millennium exclusive rights for the manufacture and distribution world wide of Medigard's blood collection device and blood flash needle. Sol Millennium Medical will complete any further regulatory requirements for both the blood collection device and the blood flash needle. In return Medigard will receive royalties based on (and varying with) the sales price of the products. The agreement also provides Sol Millennium Medical with the option to consider the commercialization of Medigard's other products.

Medigard Ltd. reported earnings results for the half year ended December 31, 2012. For the period, the company reported net loss of AUD 152,496 or AUD 0.168 per basic share on revenue of AUD 4,506 compared to net loss of AUD 162,550 or AUD 0.178 per basic share on revenue of AUD 13,642 reported a year ago. Loss before income tax expense was AUD 152,496 compared to AUD 162,550 reported a year ago. Net cash outflow from operating activities was AUD 111,199 compared to AUD 132,105 reported a year ago. Payment for intangible assets was AUD 19,571 compared to AUD 1,576 reported a year ago.

Medigard Ltd. announced that they will report first half, 2013 results on Feb 28, 2013